Verve Therapeutics, Inc.
VERV
Price:
$5.54
Market Cap:
$468.82M
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and ...[Read more]
Industry
Biotechnology
IPO Date
2021-06-17
Stock Exchange
NASDAQ
Ticker
VERV
The ROE as of September 2024 (TTM) for Verve Therapeutics, Inc. (VERV) is -35.20%
According to Verve Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -35.20%. This represents a change of 296.84% compared to the average of -8.87% of the last 4 quarters.
Verve Therapeutics, Inc. (VERV) Historical ROE (quarterly & annually)
How has VERV ROE performed in the past?
The mean historical ROE of Verve Therapeutics, Inc. over the last ten years is 14.68%. The current -35.20% ROE has changed -339.83% with respect to the historical average. Over the past ten years (40 quarters), VERV's ROE was at its highest in in the December 2020 quarter at 36.82%. The ROE was at its lowest in in the March 2020 quarter at -94.53%.
Average
14.68%
Median
-28.57%
Minimum
-33.37%
Maximum
97.27%
Verve Therapeutics, Inc. (VERV) ROE by Quarter and Year
Discovering the peaks and valleys of Verve Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 16.82%
Maximum Annual ROE = 97.27%
Minimum Annual Increase = -146.59%
Minimum Annual ROE = -33.37%
| Year | ROE | Change |
|---|---|---|
| 2023 | -33.37% | 16.82% |
| 2022 | -28.57% | -13.95% |
| 2021 | -33.20% | -146.59% |
| 2020 | 71.26% | -26.74% |
Verve Therapeutics, Inc. (VERV) Average ROE
How has VERV ROE performed in the past?
The current ROE of Verve Therapeutics, Inc. (VERV) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-31.71%
5-year avg
14.68%
10-year avg
14.68%
Verve Therapeutics, Inc. (VERV) ROE vs. Peers
How is VERV’s ROE compared to its peers?
Verve Therapeutics, Inc.’s ROE is greater than Adaptive Biotechnologies Corporation (-71.96%), greater than Beam Therapeutics Inc. (-16.22%), greater than Caribou Biosciences, Inc. (-34.76%), greater than Sana Biotechnology, Inc. (-71.60%), greater than Intellia Therapeutics, Inc. (-49.70%), greater than Editas Medicine, Inc. (-62.61%), greater than CRISPR Therapeutics AG (-13.85%), greater than Prime Medicine, Inc. (-113.34%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than aTyr Pharma, Inc. (-56.83%), greater than Relay Therapeutics, Inc. (-43.66%), greater than Century Therapeutics, Inc. (-65.37%), greater than Blueprint Medicines Corporation (-85.25%),
| Company | ROE | Market cap |
|---|---|---|
| -71.96% | $674.68M | |
| -16.22% | $2.13B | |
| -34.76% | $182.08M | |
| -71.60% | $989.97M | |
| -49.70% | $2.19B | |
| -62.61% | $315.88M | |
| -13.85% | $4.09B | |
| -113.34% | $447.11M | |
| -24.51% | $181.50M | |
| -56.83% | $131.12M | |
| -43.66% | $1.32B | |
| -65.37% | $136.39M | |
| -85.25% | $5.45B |
Build a custom stock screener for Verve Therapeutics, Inc. (VERV) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verve Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Verve Therapeutics, Inc. (VERV) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Verve Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Verve Therapeutics, Inc.'s ROE?
How is the ROE calculated for Verve Therapeutics, Inc. (VERV)?
What is the highest ROE for Verve Therapeutics, Inc. (VERV)?
What is the 3-year average ROE for Verve Therapeutics, Inc. (VERV)?
What is the 5-year average ROE for Verve Therapeutics, Inc. (VERV)?
How does the current ROE for Verve Therapeutics, Inc. (VERV) compare to its historical average?